Physician profile
Manesh Thomas
NPI 1962460550
$2,805.87
in general payments reported to CMS, 2019-2025
35 companies · $86.41 in 2025
The $86.41 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $55.45 · 2021: $856 · 2022: $378 · 2023: $517 · 2024: $682 · 2025: $86.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $226.00 | 2019-2024 | Lifevest |
| Preventric Diagnostics, INC. | $223.56 | 2021 | |
| Abbott Laboratories | $218.65 | 2019-2025 | Jot Dx |
| Irhythm Technologies, INC. | $189.64 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $183.98 | 2019-2024 | Watchman Flx, Comet |
| Bard Peripheral Vascular, INC. | $167.48 | 2021 | |
| Pfizer INC. | $154.42 | 2019-2024 | |
| Angiodynamics, INC. | $152.69 | 2020-2023 | Auryon Laser System 100-120 Vac |
| Actelion Pharmaceuticals US, INC. | $147.90 | 2022-2024 | Opsumit, Uptravi |
| Baxter Healthcare | $124.08 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.94 | 2023-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $92.91 | 2022-2024 | Verquvo |
| Kestra Medical Technology Services, INC. | $85.45 | 2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $75.64 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $74.64 | 2021-2024 | Xarelto |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.42 | 2019-2025 | |
| Edwards Lifesciences Corporation | $63.73 | 2022-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $45.47 | 2019 | |
| Cardiovascular Systems INC. | $43.70 | 2020-2021 | |
| Organogenesis INC. | $43.45 | 2022 | |
| Inspire Medical Systems, INC. | $31.72 | 2023-2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $30.51 | 2021-2024 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $28.33 | 2024 | Arcalyst |
| Medtronic, INC. | $27.70 | 2023-2024 | Corevalve Evolut R |
| Alnylam Pharmaceuticals INC. | $25.28 | 2023 | |
| Lundbeck LLC | $24.28 | 2019 | |
| Daiichi Sankyo INC. | $24.13 | 2023 | Injectafer |
| Veryan Medical Incorporated | $20.61 | 2021 | |
| Biotronik INC. | $19.41 | 2022 | |
| Terumo Medical Corporation | $18.95 | 2022 | |
| Philips North America LLC | $16.63 | 2022 | |
| Medtronic Vascular, INC. | $14.86 | 2019 | |
| Cardiofocus, INC. | $14.20 | 2019 | |
| Novo Nordisk INC | $14.03 | 2023 | Ozempic |
| Abiomed | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manesh Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.